Flotek Industries Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 27% revenue growth and 44% higher adjusted EBITDA, driven by record Data Analytics and resilient Chemistry performance. Guidance for 2026 implies continued double-digit growth, with strong backlog and expanding high-margin services.
Fiscal Year 2025
-
Record 2025 revenue and profit growth driven by data analytics and PowerTech integration, with recurring high-margin contracts and robust outlook for 2026. Chemistry segment showed resilience despite market headwinds, and CapEx is set to rise to support expansion.
-
Q3 2025 saw 13% revenue growth, 95% higher gross profit, and a 142% jump in adjusted EBITDA year-over-year, driven by record data analytics and chemistry segment performance. Guidance for 2025 was raised, with PWRtek and XSPCT assets fueling future high-margin growth and international expansion, especially in the Middle East.
-
The session highlighted a successful turnaround driven by innovation in real-time data analytics and recurring revenue models, with significant EBITDA growth and a major shift away from cyclical oilfield services. The company is expanding its addressable market, focusing on data-driven solutions, and exploring both organic and inorganic growth opportunities.
-
A multi-year transformation has driven strong financial growth, with data analytics now a core, high-margin segment expected to contribute over 60% of EBITDA by 2026. Market share and recurring revenue have surged, supported by technology innovation and international expansion.
-
Revenue grew 26% year-over-year, led by a 189% surge in data analytics and 38% growth in chemistry. Gross profit rose 57%, with adjusted net income up 202%. Data analytics is set to drive future profitability, while guidance remains conservative for chemistry amid market volatility.
-
Record quarterly growth driven by strong performance in both chemistry and data analytics, highlighted by a major acquisition and a $160M contract. 2025 guidance calls for double-digit revenue and EBITDA growth, with recurring revenues and margin expansion expected.
-
A multi-year turnaround has driven sustained financial improvement, market share gains, and innovation in both chemistry and data analytics. Regulatory trends and a shift to Data as a Service underpin future growth, while revenue diversification and M&A remain strategic priorities.
Fiscal Year 2024
-
Q4 and full year 2024 delivered record revenue, margin, and EBITDA growth, with strong gains in both chemistry and data analytics segments, driven by international expansion and new product launches. Leverage fell sharply, and 2025 is expected to see continued momentum and higher CapEx for data analytics.
-
Q3 2024 saw 5% year-over-year and 8% sequential revenue growth, with net income nearly doubling and Adjusted EBITDA up 43%. Data Analytics and Chemistry segments both expanded, and 2024 guidance was raised as recurring revenue from flare monitoring accelerates.
-
A multi-year turnaround delivered sustained EBITDA growth, expanded recurring revenue in data analytics, and significant market share gains in completions chemistry. Real-time measurement technologies are driving regulatory compliance and transparency, with strong growth and scalability plans in place.
-
Q2 2024 saw 14% sequential revenue growth and strong profitability, with external chemistry sales up 40% and data analytics up 22%. Raised full-year adjusted EBITDA guidance by 23% at midpoint, and EPA approval of JP3 Analyzer opens a $220M annual market for flare monitoring.